Disease · MONDO_0007727
TNF receptor 1-associated periodic fever syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. TNF receptor 1-associated periodic fever syndrome. Diseases, record MONDO_0007727. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007727
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
FHF, Hibernian fever, familial, TNF receptor 1 associated periodic syndrome, TNF receptor-associated periodic syndrome, TRAPS, TRAPS syndrome, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, familial Hibernian fever, tumor necrosis factor receptor 1 associated periodic syndrome, tumour necrosis factor receptor 1 associated periodic syndrome, tumour necrosis factor receptor-associated periodic syndrome
- Open Targets
Drugs1
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here |
|---|---|---|---|---|---|---|---|
| CANAKINUMAB | CHEMBL1201834 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 |
Source Drugs and targets
Targets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| IL1B | Interleukin-1 beta | 1 | Interleukin-1 beta inhibitor | Phase 3 | https://conductscience.org/library/genes/3553 |
Source Drugs and targets
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02059291 | Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers | Phase 3 | 203 | 2017-03-17 | Hereditary Periodic Fevers | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02334748 | A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies | Phase 3 | 31 | 2020-05-19 | Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01242813 | Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). | Phase 2 | 20 | 2016-02-04 | TNF-receptor Associated Periodic Syndromes (TRAPS) | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02911857 | An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes | Phase 3 | 4 | 2018-08-20 | Periodic Fevers Syndrome | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06838143 | Ilaris NIS in Korea | 25 | Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS), Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD), Systemic Juvenile Idiopathic Arthritis (sJIA) | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007727
GET https://conductscience.org/api/diseases/v1/MONDO_0007727/drugs